Page 183 - Read Online

Ravegnini et al. Cancer Drug Resist 2019;2:107-15 I http://dx.doi.org/10.20517/cdr.2019.02 Page 115

gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008;14:4550-5.
53. Lee JL, Kim JY, Ryu MH, Kang HJ, Chang HM, et al. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal
associated with neurofibromatosis type 1. Dig Dis Sci 2006;51:1043-6.
54. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic
and molecular genetic study of 45 cases. Am J Surg Pathol 2006;30:90-6.
55. Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, et al. Evidence and resources to implement pharmacogenetic
knowledge for precision medicine. Am J Heal Pharm 2016;73:1977-85.
56. Ravegnini G, Nannini M, Sammarini G, Astolfi A, Biasco G, et al. Personalized medicine in gastrointestinal stromal tumor (GIST):
clinical implications of the somatic and germline DNA analysis. Int J Mol Sci 2015;16:15592-608.
57. Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, et al. Drug transporters and imatinib treatment: implications for clinical
practice. Clin Cancer Res 2011;17:406-15.
58. Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, et al. Genetic polymorphisms in angiogenesis-related genes are
associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. Eur J
Cancer 2017;86:226-32.
59. Zhang Q, Xu J, Qian Y, Chen L, Li Q, et al. Association of imatinib plasma concentration and single-nucleotide polymorphisms with
adverse drug reactions in patients with gastrointestinal stromal tumors. Mol Cancer Ther 2018;17:2780-7.
60. Liu J, Chen Z, Chen H, Hou Y, Lu W, et al. Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma
levels and adverse reactions in chinese GIST patients. Int J Mol Sci 2017;18:603.
61. Kloth JSL, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, et al. Genetic polymorphisms as predictive biomarker of survival in
patients with gastrointestinal stromal tumors treated with sunitinib. Pharmacogenomics J 2018;18:49-55.
62. Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first
case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol 2016;29:551-6.
63. Yang J, Ikezoe T, Nishioka C, Takezaki Y, Hanazaki K, et al. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib
induces epigenetic silencing of the PTEN gene. Int J cancer 2012;130:959-66.
64. Jasek K, Kasubova I, Holubekova V, Stanclova A, Plank L, et al. Epigenetics: an alternative pathway in GISTs tumorigenesis.
Neoplasma 2018;65:477-93.
65. Yun S, Kim WK, Kwon Y, Jang M, Bauer S, et al. Survivin is a novel transcription regulator of KIT and is downregulated by
miRNA-494 in gastrointestinal stromal tumors. Int J cancer 2018;142:2080-93.
66. Zhang Z, Jiang NY, Guan RY, Zhu YK, Jiang FQ, et al. Identification of critical microRNAs in gastrointestinal stromal tumor patients
treated with Imatinib. Neoplasma 2018;65:683-92.
67. Pantaleo MA, Ravegnini G, Astolfi A, Simeon V, Nannini M, et al. Integrating miRNA and gene expression profiling analysis revealed
regulatory networks in gastrointestinal stromal tumors. Epigenomics 2016;8:1347-66.
68. Ravegnini G, Urbini M, Simeon V, Genovese C, Astolfi A, et al. An exploratory study by DMET array identifies a germline signature
associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J 2018; doi: 10.1038/s41397-018-0050-4.
69. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, et al. Folate-related polymorphisms in gastrointestinal stromal tumours:
susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet 2015;23:817-23.
70. Ravegnini G, Nannini M, Simeon V, Musti M, Sammarini G, et al. Polymorphisms in DNA repair genes in gastrointestinal stromal
tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumour Biol 2016;37:13413-23
71. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are
associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol
Res 2013;68:1-6.